DANAHER CORP /DE/ Q3 FY2024 earnings call

• Team delivered strong third quarter results with revenue, adjusted net earnings per share, and cash flow ahead of expectations.
• Positive momentum in bioprocessing and exceptional quarter at Cepheid; new innovations across businesses.
• Portfolio transformation creating a focused life sciences and diagnostics leader.
• Specific product launches: Beckman Coulter's DxC 500i, IDT's Rapid Genes; acquisition of Genedata; progress with Abcam integration.

Biotechnology Segment

• Core revenue flat year-over-year. Bioprocessing up low single-digits, discovery and medical down high single-digits. Orders increased high single-digits sequentially with a book-to-bill ratio of approximately 1.0. Full-year expected low single-digit core revenue decline, including high single-digit growth in Q4.

Life Sciences Segment

• Core revenue decreased 2%. Instruments businesses collectively mid-single-digit decline, with consumables and service growth offset by capital equipment decline (especially in China). Beckman Coulter introduced Cydem VT, acquired Genedata. Genomics consumables down low single-digits, IDT launched Rapid Genes.

Diagnostics Segment

• Core revenue increased 5%. Clinical diagnostics low single-digit growth (Beckman up low single-digits, China impacted by volume-based procurement; outside China, recurring revenue up high single-digits). Cepheid core revenue up double-digits, respiratory revenue ~$425M vs ~$200M expected, non-respiratory reagent portfolio mid-teens growth.

• Full-year 2024: Core revenue decline in low single-digit percent range, adjusted operating profit margin ~29%.
• Fourth quarter: Core revenue decline in low single-digit percent range, adjusted operating profit margin ~30%.

• Uncertainty in China stimulus implementation affecting orders.
• Volume-based procurement in China impacting diagnostics revenue.
• Elevated valuations in M&A market.
• Respiratory seasonality impacting Cepheid's revenue.

Q: Probe into instrument numbers, growth ex-China, and funnel dynamics A: Matt McGrew said instrument growth ex-China is low to mid-single-digit. Rainer Blair noted end markets stable in developed markets but early signs of improvement in pharma/biotech, especially North America; China stimulus not translating to meaningful orders yet Q: Follow-up on 2025 guidance for life sciences and China bioprocess A: Rainer Blair said still looking at Q4 to see stimulus pickup; Matt McGrew mentioned gradual recovery in bioprocessing expected in 2025 Q: Cepheid respiratory revenue beat, market share gain A: Matt McGrew said significant portion of respiratory revenue beat likely due to pull-forward; market share gain largely in US, especially with IDNs expanding into point-of-care settings Q: Genomics trends, Rapid Genes impact A: Rainer Blair said gene reading markets softer in smaller customers, but gene editing and Rapid Genes launch expected to provide tailwind Q: Q4 operating margin, margin implications for 2025 A: Matt McGrew said Q4 margin ~30% due to factors like lower respiratory revenue, timing of bioprocessing, and cost structure management; incremental margins for 2025 depend on volume and mix Q: Small customers in bioprocessing, revenue percentage A: Matt McGrew said ~25% of revenues from smaller customers, differing in funding environment and project prioritization from larger customers Q: Buyback, M&A funnel A: Matt McGrew said buyback completed, straddling Q2 and Q3; Rainer Blair said active in M&A, with funnels dynamic but valuations elevated Q: China bioprocess outlook, local competition A: Rainer Blair said China stable, bumping along bottom unless stimulus execution changes; local competition exists, but some customers buy least expensive solutions while others prefer multinational companies Q: Abcam performance A: Rainer Blair said no other M&A in Abcam revenue mix; team making progress with Danaher integration, using DBS capabilities to drive growth and cost improvements Q: Diagnostics in China, regional dynamics A: Matt McGrew said China diagnostics revenue down low double-digits; Rainer Blair said strong performance in clinical diagnostics globally except China, impacted by volume-based procurement